Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Nintedanib in Hepatic Impairment
NCT02191865Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of nintedanib in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Curve (0-infinity) at 168 hours and Maximum Plasma Concentration at 168 hours. Started Jul 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02191865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191865.